The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Ozcelik, M.; Odabas, H.; Ercelep, O.; Yuksel, S.; Mert, A.; Aydin, D.; Surmeli, H.; Isik, D.; Isik, S.; Oyman, A.; Ustaalioglu, B.; ALİUSTAOĞLU, MEHMET; Gumus, M.

doi:10.1007/s12094-015-1408-6

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Copy For Citation

Ozcelik M., Odabas H., Ercelep O., Yuksel S., Mert A. G., Aydin D., ...More

CLINICAL & TRANSLATIONAL ONCOLOGY, vol.18, no.6, pp.617-624, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 18 Issue: 6
Publication Date: 2016
Doi Number: 10.1007/s12094-015-1408-6
Journal Name: CLINICAL & TRANSLATIONAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.617-624
Kütahya Health Sciences University Affiliated: No

Abstract

The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens.